氯吡格雷治疗高危不稳定型心绞痛56例

PLAVIX IN HIGH RISK UNSTABLE ANGINA:A REPORT OF 56 CASES

目的 观察氯吡格雷治疗高危不稳定型心绞痛的心脏事件、出血风险和预后影响。方法 高危或极高危不稳定型心绞痛患者1 0 2例 ,予内科强化治疗 :硝酸酯类、阿司匹林、β受体阻滞剂、钙离子拮抗剂、调脂药物、皮下注射低分子肝素抗凝 7d ,其中 56例口服氯吡格雷片 75mg/d ,连用 1～ 3个月。主要观察终点 :随访治疗 30d内发生急性心肌梗死 ,心脏性或非心脏性死亡和药物治疗无法控制的心绞痛 ,需行血运重建术。住院至少 7d ,随访至治疗后 30d。结果 加服氯吡格雷使平均胸痛发作次数减少 ,需口服硝酸甘油缓解胸痛者减少 ,复合终点事件 (死亡、心肌梗死和紧急血运重建 )明显下降。结论 加服氯吡格雷片可明显改善高危不稳定型心绞痛复合事件的发生率 ,应用安全。

Objective To evaluate the efficacy and safety of Prechigh risk unstable angina. Methods 102 high risk unstable angina cases received baseline clinical therapy, including 56 cases plused with Plavix 75mg/day for 1～3months. The patients enrolled hospital at least 7 days, and then all the patients had followed-up for 30 days after hospitalization. The primary end points were myocardial infarction, cardiac or noncardiac death and urgent revascularization. Results Ingroup Plavix patients receiving oral nitroglyceyin for pain relief were reduced and the incidence of angina pectoris was reduced too. By 30 days follow-up, both death and composite and point(death myocrdial infarcation and urgent revascularization)were significantly reduced in patients receiving Plavix. Conclusion Plavix is effective on reducing death and composite cardiovascular events.